The Filing Desk

Elutia

ELUT · Nasdaq · Health Care · Financials, fiscal 2019 to 2025

ELUT · Last close · November 19, 2026
$0.81
Value Elutia yourself

Elutia's revenue fell 15.0% to $12 million in fiscal 2025. Its operating margin was −218.9%, down from −212.3% a year earlier. Free cash flow was −$47 million. The diluted share count rose 58.0%.

Elutia Inc. Latest fiscal year ended December 31, 2025 10-K filed March 13, 2026 · 0001104659-26-027664 Updated
Revenue
$12M
15.0%
Operating margin
−218.9%
6.6 pts
Net income
$53M
 
Free cash flow
−$47M
 
Return on equity
—
 
Market cap
$38M
Nov 19 close
P/E
—
 

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Piotroski F-score for fiscal 2025 is blank: the 10-K's structured data doesn't include short-term borrowings.

Charts show fiscal years, from the 10-K filings.

What Elutia does

Elutia makes biologic matrices: thin sheets of processed human or animal tissue that surgeons use to repair and support soft tissue. It sells SimpliDerm, made from donated human skin and used mainly in breast reconstruction after cancer surgery, and patches made from pig intestine tissue, called ProxiCor, Tyke and VasCure, used to repair the heart and blood vessels. It sells them to US hospitals and other healthcare facilities through independent sales agents, and relies on single suppliers for each product line.

The company reports two segments, Women's Health (SimpliDerm) and Cardiovascular. Total sales fell to $12.3 million in 2025, mostly because of lower SimpliDerm sales. It names AbbVie's AlloDerm and Strattice, Stryker's DermACELL and Integra's SurgiMend among the products SimpliDerm competes with, and Gore and Terumo among the makers of patches that compete with its heart products.

In October 2025 Elutia sold its business of envelopes that hold heart devices such as pacemakers, EluPro and CanGaroo, to Boston Scientific for up to $88.0 million in cash. It now focuses on developing NXT-41, a new tissue matrix, and a version of it that slowly releases antibiotics at the surgical site to help prevent infection; both need FDA clearance before they can be sold. It is based in Gaithersburg, Maryland, and had 26 employees at the end of 2025.

Its biggest risks, as it describes them

  • It faces lawsuits over recalls of two bone graft products it used to sell, and has no more insurance for one of them.
  • Its new products need FDA clearance, which may be slow or may not come at all.
  • It may need to raise more money, which may not be available on acceptable terms.
  • Surgeons and hospitals may not adopt its products, especially where insurers do not pay for procedures that use them.
  • Competition from larger companies with longer histories, more established products and more resources.
From Elutia's annual report on Form 10-K, filed March 13, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow
Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments3017191336
Debt incl. finance leases26—2424—
Net debt (negative means net cash)−4—411—
Net debt to EBITDA—————
Debt to equity2.0x————
Interest coverage−4.3x−6.9x−5.3x−6.4x−3.6x
Current ratio1.8x1.2x0.7x0.7x2.2x
Quick ratio1.5x1.1x0.6x0.6x2.1x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Elutia's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 7 insiders bought $215,115 of Elutia shares on the open market, and none sold any.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Jan 30, 2026Kevin RakinDirector, 10% ownerBought70,000$1.06$74,200Form 4
Jan 30, 2026Guido J NeelsDirectorBought20,000$1.04$20,800Form 4
Jan 29, 2026Guido J NeelsDirectorBought15,000$1.06$15,900Form 4
Jan 28, 2026Guido J NeelsDirectorBought15,000$1.06$15,900Form 4
Dec 17, 2025Matthew FergusonChief Financial OfficerBought60,000$0.53$31,800Form 4
Dec 17, 2025HighCape Partners GP II LLC10% ownerBought50,000$0.52$26,000Form 4
Dec 17, 2025Brigid MakesDirectorBought25,000$0.52$13,000Form 4
Dec 17, 2025David ColpmanDirectorBought12,500$0.51$6,375Form 4
Dec 17, 2025Mills C RandalPresident and CEO, DirectorBought3,000$0.51$1,530Form 4
Dec 2, 2025Matthew FergusonChief Financial OfficerBought5,500$0.67$3,685Form 4
Dec 1, 2025Matthew FergusonChief Financial OfficerBought4,500$0.65$2,925Form 4
Nov 24, 2025Mills C RandalPresident and CEO, DirectorBought5,000$0.60$3,000Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score—2 of 9—
Rule of 40−85.6%−202.7%−394.8%
Altman Z''−20.18−29.13−8.05
Accruals ratio−28.3%−78.7%199.4%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailPass
Cash from operations is positiveFailFailFail
Return on assets roseFailFailPass
Cash from operations exceeds net incomePassPassFail
Debt fell relative to assets—Fail—
Current ratio roseFailFailPass
Share count didn't riseFailFailFail
Gross margin roseFailPassPass
Revenue rose relative to assetsPassFailPass
F-score—2 of 9—
Companies that report no gross profit are scored on the other eight.

Compare

Put Elutia side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
ElutiaFY25−15.0%−218.9%−379.8%———
Nano-X ImagingFY2515.4%−600.8%−345.6%———Compare
NexgelFY2531.5%−29.4%−12.1%———Compare
CapsoVisionFY2515.3%−188.2%−169.3%———Compare
HyperfineFY255.2%−273.4%−214.8%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

7 years of figures

Fiscal yearFY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue43434724251412
Revenue growth—−0.5%11.0%−49.7%3.8%−41.5%−15.0%
Gross profit202119121177
Research and development2698434
Operating income−8−14−23−35−30−31−27
Net income−12−22−25−33−38−5453
Diluted EPS (US$)−18.48−8.88−2.38−2.38−2.07−1.860.87
Diluted shares (millions)131014182946
Cash flow
Cash from operations−7−14−15−21−22−23−45
Capital expenditure1100012
Free cash flow−8−14−16−22−22−23−47
Dividends paid0000000
Share buybacks0000000
Acquisitions0000000
Stock-based compensation0144285
Balance sheet at fiscal year end
Cash and short-term investments2393017191336
Debt incl. finance leases213026—2424—
Total assets45836769433662
Total liabilities55625474828235
Shareholders' equity−552114−5−39−4628
Margins and ratios
Gross margin46.1%48.2%40.1%48.8%44.7%46.4%53.7%
Operating margin−19.6%−31.9%−48.6%−147.6%−123.4%−212.3%−218.9%
Net margin−27.8%−51.1%−52.4%−137.9%−152.2%−372.9%434.2%
Free cash flow margin−18.2%−33.4%−33.4%−92.1%−89.3%−161.1%−379.8%
Rule of 40 (growth + FCF margin)—−33.9%−22.3%−141.8%−85.6%−202.7%−394.8%
Return on capital——−167.2%————
Return on equity——−144.6%−775.1%———
Return on assets—−34.2%−33.1%−48.4%−67.1%−135.6%108.4%
Net debt to EBITDA———————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Elutia's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Elutia.